New Photoimmunotherapy Shows Promise for Throat Cancer
In a study of patients with head and neck cancer, a new combination therapy linked to 28.2 months median survival.
Updated on Oct. 23, 2026 in Cancer
Live Poll
Should cancer treatments be fast-tracked based on smaller, early-phase clinical study results?
Updated data for the ASP-1929 and pembrolizumab combination therapy shows a median overall survival of 28.2 months in patients with recurrent or metastatic head and neck squamous cell carcinoma. These findings were presented at the 2026 European Society for Medical Oncology congress.
Why it matters
Researchers are investigating whether this photoimmunotherapy can provide more durable tumor control when combined with standard treatments. The results offer long-term insight for patients with advanced disease, though the findings come from a small cohort of 17 evaluable patients.
A follow-up of a small study involving 17 evaluable patients reported a median overall survival of 28.2 months and a median response duration of 44.3 months. Because the study included a limited number of participants, these preliminary findings require validation in larger trials.
The players
Rakuten Medical
A biotechnology company developing precision cancer therapies, including photoimmunotherapy platforms.
The details
ASP-1929 is an antibody-dye conjugate that researchers activate using 690 nm non-thermal red light to trigger selective cancer cell necrosis. By combining this photoimmunotherapy with the immunotherapy drug pembrolizumab, the study aims to enhance durability in patients with recurrent or metastatic head and neck squamous cell carcinoma. At a data cutoff after a 53.1-month median follow-up, one-third of the patients remained alive at four years.
Timeline
December 2, 2018: Study NCT03769506 was registered.
September 2020: ASP-1929 received conditional marketing approval in Japan.
June 24, 2021: The Phase I Japanese study was published.
January 23, 2025: The global Phase 3 study, NCT06699212, was initiated.
October 2026: The follow-up data were presented at ESMO 2026.
Health Landscape
This development represents a progress update on experimental photoimmunotherapy as a potential addition to standard first-line cancer regimens. It aligns with broader efforts to increase durable survival rates in advanced head and neck cancers, pending results from the global Phase 3 trial.
Patients currently managing recurrent or metastatic head and neck squamous cell carcinoma should consult their oncologist about ongoing clinical trial opportunities. It is essential to discuss whether new combination therapies under investigation may be relevant to your specific clinical situation.
The takeaway
These findings highlight a potential long-term survival benefit for a small group of patients receiving experimental photoimmunotherapy. If you are tracking new cancer treatment developments, continue monitoring results from the broader ASP-1929 phase 3 trials in the coming years.
What happens next
Rakuten Medical plans to submit a U.S. BLA filing in 2028, provided that the ongoing Phase 3 study, which aims for an enrollment of 400 to 412 patients, proves successful.
Further reading
For more information on current treatment research, visit our Cancer section.
More information
View full details on the Phase 3 clinical trial study registry.
Source note: This article includes information reported by The Clinical Trial Vanguard - Your premier source for the latest clinical trial news.
Live Poll
Should cancer treatments be fast-tracked based on smaller, early-phase clinical study results?
